Onconetix Inc Ordinary Shares ONCO 深 沪
等待开盘 12-19 09:30:00 美东时间
1.84
-0.070
-3.66%
华盛通- 最 高2.0499
- 今 开1.89
- 成交量 12.33万股
- 最 低 1.84
- 昨 收 1.91
- 总市值 284.41万
- 52周最高 179.35
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.84
- 委 比 60.00%
- 总股本 154.57万
- 历史最高 309060.00
- 量 比 2.07
- 振 幅 10.99%
- 历史最低 1.84
- 每 手 1
- 风险率 16.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Onconetix Q3 EPS $(6.25) Up From $(249.05) YoY, Sales $303.651K Down From $406.859K YoY
Onconetix (NASDAQ:ONCO) reported quarterly losses of $(6.25) per share. This is a 97.49 percent increase over losses of $(249.05) per share from the same period last year. The company reported $303.651 thousand in sales
11-14 06:29
Onconetix Files Prospectus For Resale Of 22.1M Shares Of Common Stock By Selling Stockholders
-SEC Filing
11-05 06:44
Onco-Innovations launches $2M private placement offering
Onco-Innovations (NEOE:ONCO:CA) plans a non-brokered private placement of up to 1.43M units at $1.40 per unit, targeting $2M in gross proceeds. Each unit includes one common share and half a warrant; ...
10-15 13:51
Oncopeptides Issues Warrants to Meet EIB Loan Obligations
Oncopeptides AB ( ($SE:ONCO) ) has provided an announcement. Oncopeptides AB ha...
10-14 01:02
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Major pharmaceutical companies presenting at...
10-07 20:00
Onconetix Completes PIPE Financing Transaction
The latest announcement is out from Onconetix ( ($ONCO) ). On October 1, 2025, ...
10-03 20:48
Onco-Innovations Advances Preclinical Program with Nucro-Technics Collaboration
Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an announcement. Onco-Innova...
09-30 03:08
Onconetix Completes $12.9M Private Placement
Onconetix ( ($ONCO) ) has issued an announcement. On September 22, 2025, Oncone...
09-26 21:15
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
Onconetix, Inc. completed a $12.9 million private placement of Series D Convertible Preferred Stock and warrants, with $9.3 million paid in cash and $3.6 million used to offset debts. The Series D Preferred Stock is convertible into 4.36 million shares of common stock, and the warrants have an exercise price of $3.6896 per share. Proceeds will be used to terminate a previous business combination with Ocuvex and for working capital. Onconetix also...
09-26 12:30
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths. Both companies remain committed to advancing their missions and delivering value to patients. Ocuvex has received its New Jersey state pharmaceutical license and is set to launch Omlonti commercially in the coming weeks. Onconetix and Ocuvex appreciate the collaborative spirit during the merger discussions.
09-26 12:15
